Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589693 | 0.88 | NCF1 (0.33) | NCF1HRH3ACHEKDM4E | |
| SCHEMBL81624 | 0.82 | L3MBTL1 (0.39) | NCF1HRH3ACHEPIM1L3MBTL1 | |
| SCHEMBL22570309 | 0.81 | MEN1 (0.45) | NCF1HRH3ACHEMEN1KMT2A | |
| SCHEMBL7943522 | 0.81 | MEN1 (0.45) | NCF1HRH3ACHEMEN1KMT2A | |
| SCHEMBL22570156 | 0.81 | MEN1 (0.45) | NCF1HRH3ACHEMEN1KMT2A | |
| SCHEMBL4701914 | 0.80 | GRIN2B (0.35) | HRH3 | |
| SCHEMBL17574067 | 0.79 | NCF1 (0.35) | NCF1HRH3ACHEMEN1KMT2A | |
| SCHEMBL16731641 | 0.79 | NCF1 (0.35) | NCF1HRH3ACHEMEN1KMT2A | |
| SCHEMBL14013459 | 0.79 | NCF1 (0.61) | NCF1HRH3ACHEMEN1KMT2A | |
| SCHEMBL22179237 | 0.79 | NCF1 (0.35) | NCF1HRH3ACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | NCF1 623/4885HRH3 3567/4885ACHE 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.